← Back to Search

Cannabinoid Therapy

Medical Cannabis for Chronic Pain

Minneapolis, MN

N/A

Waitlist Available

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Normal or corrected-to-normal vision and hearing

Be older than 18 years old

Must not have

Degenerative neurological condition or neurological condition impacting brain function (e.g., epilepsy)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessed at baseline and after four months

Awards & highlights

No Placebo-Only Group

Summary

This trial will study how medical cannabis affects cognitive function and brain activity in chronic pain patients. They will compare the effects of CBD-dominant and THC-dominant products and track participants over four months

See full description

Who is the study for?

This trial is for adults aged 35-65 with chronic pain, prioritizing those with orthopedic issues. Participants must be new medical cannabis users or non-users, able to perform tasks and communicate by phone. They should not have a history of substance abuse or severe psychiatric conditions, and cannot be pregnant or recent mothers.Check my eligibility

What is being tested?

The study tests how different cannabis compounds (CBD vs THC) affect cognition and brain function in chronic pain patients using medical cannabis. It involves initial assessments, monthly check-ins, and follow-up testing including fMRI scans and cognitive evaluations over four months.See study design

What are the potential side effects?

While the study itself may not directly cause side effects, participants' use of medical cannabis could lead to changes in attention, memory impairment, altered brain function or connectivity which will be monitored through various neurocognitive tests.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My vision and hearing are normal, or corrected to be normal.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a brain condition like epilepsy.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ administered at baseline and after four months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~administered at baseline and after four months

This trial's timeline: 3 weeks for screening, Varies for treatment, and administered at baseline and after four months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Blood levels of cannabinoid compounds

CANTAB Self-Ordered Search Task

CANTAB Spatial Paired Associates Learning Task

+16 more

Secondary study objectives

Alcohol Use Disorders Identification Test (AUDIT)

Beck Depression Inventory (BDI)

Brief Pain Inventory

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental cognitive and fMRI-based tasksExperimental Treatment3 Interventions

One primary aim of this study is to examine cognitive functioning in individuals who use medical cannabis. All participants in the study will complete cognitive measures that include measures of attention, learning, memory and executive function. All participants will complete task fMRI-based measures of learning and inhibitory control. NIH considers the cognitive and fMRI tasks to be interventions. The fMRI learning task measures face-name associative learning. The fMRI inhibitory control task is a go/no-go task whereby participants respond on some trials to "go" stimuli and withhold responses on other trials to "no-go" stimuli. Brain activations are measured in response to each task. Each participant will complete two cognitive testing sessions as well as two fMRI sessions during the course of the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cognitive testing

2018

N/A

~450

0 / 2Eligibility criteria met